The CEACAM5 drugs market is expected to grow significantly
in the coming years. This is due to the increasing number of
patients being diagnosed with cancer and the increasing number of
CEACAM5 that are under clinical trials. Currently, there are no
CEACAM5 approved by any regulatory bodies.
LAS
VEGAS, Sept. 17, 2024 /PRNewswire/ --
DelveInsight's CEACAM5 Drugs Market
Insights report includes a comprehensive understanding of
current treatment practices, emerging CEACAM5 drugs, market share
of individual therapies, and current and forecasted
CEACAM5 drugs market size from 2020 to 2034, segmented
into 7MM [the United States, the
EU4 (Germany, France, Italy, and Spain), the United
Kingdom, and Japan].
Key Takeaways from the CEACAM5 Market Report
- As per DelveInsight's analysis, the total market size of
CEACAM5 drugs in the 7MM is expected to surge significantly by
2034.
- Leading CEACAM5 drug companies such as SurgiMab, Merck
KGaA, Sanofi, Hoffmann-La Roche, and others are developing
novel CEACAM5 drugs that can be available in the CEACAM5 drugs
market in the coming years.
- Some of the key CEACAM5 drugs in the pipeline include
SGM-101, M9140, SGN-CEACAM5C, Cibisatamab +
RO7122290, and others.
- In June 2024, Merck KGaA shared
preliminary data from a Phase I study of M9140, a novel
antibody-drug conjugate (ADC) targeting CEACAM5, at the American
Society of Clinical Oncology (ASCO) Annual Meeting. This trial
included 40 patients with advanced colorectal cancer who had
previously undergone treatment, from the U.S., Europe, and Japan, and tested across seven different dose
levels. The results showed that 10% of patients experienced
a partial response, while 42.5% achieved stable disease.
With a preliminary median progression-free survival of 6.7
months, these findings indicate that M9140 could represent a
promising new treatment option for this condition.
- In December 2023, Sanofi
ended its tusamitamab ravtansine program as it missed the study's
primary endpoint and did not beat the chemotherapy docetaxel when
it came to progression-free survival. Tusamitamab ravitansine
(CEACAM5) was originated from a long-running deal between Sanofi
and ImmunoGen and evaluated as a monotherapy in previously treated
patients with metastatic non-squamous non-small cell lung cancer
(NSCLC).
Discover which therapies are expected to grab the
CEACAM5 drugs market share @ CEACAM5 Drugs Market
Report
CEACAM5 Drugs Market Dynamics
The CEACAM5 drugs market is rapidly evolving due to the
molecule's significance in the treatment of various cancers,
particularly colorectal, gastric, and non-small cell lung cancers.
One of the primary drivers of the CEACAM5 drugs market is the
increasing prevalence of cancers that overexpress CEACAM5.
As cancer rates continue to rise globally, the demand for more
effective and targeted therapies is growing, propelling the
market forward. Furthermore, advancements in biotechnology and
immunotherapy are enabling the development of innovative
CEACAM5-targeting drugs, which are showing promise in clinical
trials. These advancements are expected to expand the market
significantly in the coming years.
However, the CEACAM5 drugs market also faces challenges. One
significant barrier is the high cost of drug development and
the stringent regulatory requirements for new therapies. The
complex nature of biologics and the need for extensive clinical
testing before approval can lead to high development costs,
which are often passed on to consumers, limiting access to these
therapies. Additionally, the competition from other targeted
therapies and the development of resistance to current
treatments may pose further challenges to the growth of the
market.
Despite these challenges, the market outlook for
CEACAM5-targeting drugs remains positive. As research continues to
uncover more about the role of CEACAM5 in cancer progression, new
therapeutic opportunities are likely to emerge. Collaborations
between pharmaceutical companies and research institutions are
expected to accelerate the discovery and development of
next-generation CEACAM5 therapies, potentially leading to more
effective treatments with fewer side effects.
CEACAM5 Drugs Treatment Market
Therapies that specifically target CEACAM5 have not yet received
regulatory approval. However, researchers are actively
investigating various strategies to inhibit CEACAM5 as a potential
treatment for cancers that overexpress this protein. Some of the
approaches under investigation include:
Small Molecule Inhibitors: Companies are developing
small molecules aimed at inhibiting CEACAM5 activity in Non-Small
Cell Lung Cancer. These inhibitors could potentially disrupt
CEACAM5-related signaling pathways involved in cancer
progression.
Antibodies Blocking CEACAM5: Monoclonal antibodies are
being engineered to bind specifically to CEACAM5, thereby blocking
its function. This could potentially inhibit tumor growth and
metastasis by disrupting CEACAM5-related processes.
Peptide-based Inhibitors: Peptides designed from the
CEACAM5 protein sequence or mimicking its binding partners are
being explored as potential inhibitors. These peptides could
interfere with CEACAM5-related cell adhesion, migration, and
invasion.
Gene Silencing: Techniques such as RNA interference
(RNAi) or CRISPR-based gene editing are being explored to silence
CEACAM5 expression in cancer cells. Reducing CEACAM5 levels could
potentially inhibit cancer cell growth and metastasis.
Combination Therapies: Inhibiting CEACAM5 could be
combined with other targeted therapies, chemotherapy, or
immunotherapy to enhance treatment effectiveness. These combination
approaches might provide synergistic effects and help overcome
resistance mechanisms.
Learn more about the FDA-approved CEACAM5 drugs @ CEACAM5
Drugs
Key Emerging CEACAM5 Drugs and Companies
Merck KGaA, Sanofi, SurgiMab, Roche, and several other
companies are currently engaged in the development and production
of selective CEACAM5 ADCs, which have the potential to
significantly impact and enhance the CEACAM5 market.
SGM-101 is a tumor-targeting antibody linked to a
near-infrared fluorochrome. It specifically binds to a marker that
is overexpressed in gastrointestinal and other types of tumors.
Currently, in Phase III trials, it is being evaluated for its
effectiveness in identifying primary and recurrent tumors, as well
as metastases, in patients undergoing colorectal cancer
surgery.
This near-infrared fluorochrome targets the CEACAM5 receptor,
which is utilized in molecular imaging to guide lung cancer
resections, particularly because the glycoprotein is present in
over 80% of adenocarcinomas.
M9140 is an experimental antibody-drug conjugate
targeting CEACAM5, designed to deliver a cytotoxic topoisomerase 1
(TOP1) inhibitor to tumor cells expressing CEACAM5. This inhibitor
enters the cell nucleus, disrupting DNA replication and repair,
leading to the death of the targeted tumor cells. Additionally, the
payload can kill nearby tumor cells through a bystander effect.
M9140 is engineered for stability in the bloodstream, with enhanced
cancer-killing efficiency and a wide therapeutic window. It also
shows potential for synergy when combined with DDR inhibition.
The anticipated launch of these emerging therapies are poised to
transform the CEACAM5 drugs market landscape in the coming years.
As these cutting-edge therapies continue to mature and gain
regulatory approval, they are expected to reshape the CEACAM5 drugs
market landscape, offering new standards of care and unlocking
opportunities for medical innovation and economic growth.
To know more about CEACAM5 drugs clinical trials, visit @
CEACAM5 Treatment Drugs
CEACAM5 Overview
Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5
(CEACAM5) is a glycoprotein that belongs to the immunoglobulin
superfamily and plays a significant role in cell adhesion,
intracellular signaling, and immune response regulation. It is
highly expressed in various epithelial cells, particularly in the
gastrointestinal tract, lungs, and pancreas. CEACAM5 is best known
for its association with carcinoembryonic antigen (CEA), a
well-established tumor marker used in the diagnosis and management
of certain types of cancer, including colorectal, gastric, and
pancreatic cancers. Elevated levels of CEACAM5 in the blood are
often indicative of malignant tumors, making it a valuable
biomarker for cancer detection and monitoring.
CEACAM5's role extends beyond its use as a diagnostic marker; it
is also involved in tumorigenesis and metastasis. The molecule can
mediate cell-cell and cell-matrix interactions, which are crucial
for the proliferation and spread of cancer cells. Due to its
overexpression in various cancers and limited expression in normal
tissues, CEACAM5 has become a target for therapeutic interventions,
including monoclonal antibodies and cancer vaccines. Ongoing
research continues to explore the potential of CEACAM5-targeted
therapies, aiming to improve the specificity and efficacy of cancer
treatment while minimizing damage to healthy tissues.
CEACAM5 Epidemiology Segmentation
The CEACAM5 drugs market report proffers epidemiological
analysis for the study period 2020–2034 in the 7MM segmented
into:
- Total Prevalent Cases in Selected Indications for
CEACAM5-specific Therapies
- Total Eligible Patient Pool for CEACAM5-specific Therapies in
Selected Indications
- Total Treated Cases in Selected Indications for
CEACAM5-specific Therapies
CEACAM5 Report
Metrics
|
Details
|
Study Period
|
2020–2034
|
CEACAM5
Report Coverage
|
7MM [The United States,
the EU-4 (Germany, France, Italy, and Spain), the United Kingdom,
and Japan]
|
Key CEACAM5 Drug
Companies
|
SurgiMab, Merck KGaA,
Sanofi, Hoffmann-La Roche, and others
|
Key CEACAM5
Drugs
|
SGM-101, M9140,
SGN-CEACAM5C, Cibisatamab + RO7122290, and others
|
Scope of the CEACAM5 Market Report
- CEACAM5 Therapeutic Assessment: CEACAM5 current
marketed and emerging therapies
- CEACAM5 Market Dynamics: Conjoint Analysis
of Emerging CEACAM5 Drugs
- Competitive Intelligence Analysis: SWOT analysis
and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, CEACAM5 Market
Access and Reimbursement
Discover more about CEACAM5 drugs in development @
CEACAM5 Drugs Clinical Trials
Table of Contents
1.
|
Key Insights
|
2.
|
Report
Introduction
|
3.
|
Executive Summary of
CEACAM5
|
4.
|
Key Events
|
5.
|
Market Forecast
Methodology
|
6.
|
CEACAM5 Drugs Market
Overview at a Glance in the 7MM
|
6.1.
|
Market Share (%)
Distribution by Indication in 2020
|
6.2.
|
Market Share (%)
Distribution by Indication in 2034
|
7.
|
CEACAM5-specific
Therapies: Background and Overview
|
7.1.
|
Introduction
|
7.2.
|
Evolution of
CEACAM5-specific Therapies
|
7.3.
|
Treatment
|
8.
|
Target Patient
Pool
|
8.1.
|
Key Findings
|
8.2.
|
Assumptions and
Rationale: 7MM
|
8.3.
|
Epidemiology Scenario
in the 7MM
|
8.3.1.
|
Total Prevalent Cases
in Selected Indications for CEACAM5-specific Therapies in the
7MM
|
8.3.2.
|
Total Eligible Patient
Pool for CEACAM5-specific Therapies in Selected Indications in the
7MM
|
8.3.3.
|
Total Treated Cases in
Selected Indications for CEACAM5-specific Therapies in the
7MM
|
8.4.
|
Epidemiology Scenario
in the US
|
8.4.1.
|
Total Prevalent Cases
in Selected Indications for CEACAM5-specific Therapies in the
US
|
8.4.2.
|
Total Eligible Patient
Pool for CEACAM5-specific Therapies in Selected Indications in the
US
|
8.4.3.
|
Total Treated Cases in
Selected Indications for CEACAM5-specific Therapies in the
US
|
8.5.
|
Epidemiology Scenario
in EU4 and the UK
|
8.5.1.
|
Total Prevalent Cases
in Selected Indications for CEACAM5-specific Therapies in EU4 and
the UK
|
8.5.2.
|
Total Eligible Patient
Pool for CEACAM5-specific Therapies in Selected Indications in EU4
and the UK
|
8.5.3.
|
Total Treated Cases in
Selected Indications for CEACAM5-specific Therapies in EU4 and the
UK
|
8.6.
|
Epidemiology Scenario
in Japan
|
8.6.1.
|
Total Prevalent Cases
in Selected Indications for CEACAM5-specific Therapies in
Japan
|
8.6.2.
|
Total Eligible Patient
Pool for CEACAM5-specific Therapies in Selected Indications in
Japan
|
8.6.3.
|
Total Treated Cases in
Selected Indications for CEACAM5-specific Therapies in
Japan
|
9.
|
Emerging
Therapies
|
9.1.
|
Key
Competitors
|
9.2.
|
SGM-101:
SurgiMab
|
9.2.1.
|
Product
Description
|
9.2.2.
|
Other developmental
activities
|
9.2.3.
|
Clinical
development
|
9.2.4.
|
Safety and
efficacy
|
9.3.
|
M9140: Merck
|
9.3.1.
|
Product
Description
|
9.3.2.
|
Other developmental
activities
|
9.3.3.
|
Clinical
development
|
9.3.4.
|
Safety and
efficacy
|
List to be continued
in the report
|
10.
|
CEACAM5-specific
Therapies: Seven Major Market Analysis
|
10.1.
|
Key Findings
|
10.2.
|
Market
Outlook
|
10.3.
|
Key Market Forecast
Assumptions
|
10.4.
|
Total Market Size of
CEACAM5 in the 7MM
|
10.5.
|
Market Size of CEACAM5
by Indication in the7MM
|
10.6.
|
The United States
Market Size
|
10.6.1.
|
Total Market Size of
CEACAM5 in the United States
|
10.6.2.
|
Market Size of CEACAM5
by Indication in the United States
|
10.6.3.
|
Market Size of CEACAM5
by Therapies in the United States
|
10.7.
|
EU4 and the UK Market
Size
|
10.7.1.
|
Total Market Size of
CEACAM5 in EU4 and the UK
|
10.7.2.
|
Market Size of CEACAM5
by Indication in EU4 and the UK
|
10.7.3.
|
Market Size of CEACAM5
by Therapies in EU4 and the UK
|
10.8.
|
Japan Market
Size
|
10.8.1.
|
Total Market Size of
CEACAM5 in Japan
|
10.8.2.
|
Market Size of CEACAM5
by Indication in Japan
|
10.8.3.
|
Market Size of CEACAM5
by Therapies in Japan
|
11.
|
Market Access and
Reimbursement
|
12.
|
SWOT
Analysis
|
13.
|
KOL Views
|
14.
|
Unmet Needs
|
15.
|
Appendix
|
15.1.
|
Bibliography
|
15.2.
|
Report
Methodology
|
16.
|
DelveInsight
Capabilities
|
17.
|
Disclaimer
|
18.
|
About
DelveInsight
|
Related Reports
Colorectal Cancer Market
Colorectal Cancer Market Insight, Epidemiology and Market
Forecast – 2032 report deliver an in-depth understanding
of the disease, historical and forecasted epidemiology, as well as
the market trends, market drivers, market barriers, and key
colorectal cancer companies, including Mirati Therapeutics,
Merck, Hutchison Medipharma, EpicentRx, Eli Lilly, Amgen, Daiichi
Sankyo, AstraZeneca, Cardiff Oncology,
NeoImmuneTech, among others.
Colorectal Cancer Pipeline
Colorectal Cancer Pipeline Insight –
2024 report provides comprehensive insights about the
pipeline landscape, pipeline drug profiles, including clinical and
non-clinical stage products, and the key colorectal
cancer companies, including Mirati Therapeutics, Exelixis,
Enterome, Arcus Biosciences, Lyell Immunopharma, AstraZeneca,
Novartis Pharmaceuticals, Surgimab, Numab Therapeutics, SOTIO
Biotech, Amgen, Sichuan Baili Pharmaceutical, Qilu Pharmaceutical,
Bristol-Myers Squibb, NGM Biopharmaceuticals, Takeda, PureTech,
Pfizer, Kezar Life Sciences, Salubris Biotherapeutics, among
others.
Metastatic Colorectal Cancer Pipeline
Metastatic Colorectal Cancer Pipeline Insight
– 2024 report provides comprehensive insights
about the pipeline landscape, pipeline drug profiles, including
clinical and non-clinical stage products, and the
key metastatic colorectal Cancer companies, including
Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited
Company, Genor Biopharma Co., Ltd., Menarini Group, Chia Tai
Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences, Inc.,
SFJ Pharmaceuticals, Merck Serono, Sumitomo Pharma Co., Ltd.,
Immunovative Therapies, Ltd., Cardiff Oncology, Symphogen A/S,
Genentech, Qilu Pharmaceutical Co., Ltd., Henlix Biotech, Scandion
Oncology A/S, Aadi Bioscience, Inc., Novartis, Roche, Boehringer
Ingelheim, Isofol Medical, Treos Bio, Suzhou Suncadia
Biopharmaceuticals Co., Ltd., Elevar Therapeutics, Shanghai Henlius
Biotech, among others.
Metastatic Colorectal Cancer Market
Metastatic Colorectal Cancer Market Insights, Epidemiology,
and Market Forecast – 2032 report deliver an in-depth
understanding of the disease, historical and forecasted
epidemiology, as well as the market trends, market drivers, market
barriers, and key metastatic colorectal cancer companies, including
Pfizer, Sanofi, Taiho Pharma, Ono Pharma, Hutchison Medipharma,
Isofol Medical, Sumitomo Dainippon Pharma, G1 Therapeutics, AB
Science, Daiichi Sankyo, Astrazeneca, Merck, Eisai, Mirati
Therapeutics, Cardiff Oncology, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market
Research firm focused exclusively on life sciences. It supports
pharma companies by providing comprehensive end-to-end solutions to
improve their performance. Get hassle-free access to all the
healthcare and pharma market research reports through our
subscription-based platform PharmDelve.
Contact Us
Shruti
Thakur
info@delveinsight.com
+14699457679
Logo:
https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/ceacam5-drugs-market-outlook-rising-cancer-cases-and-clinical-trials-to-fuel-growth-by-2034--delveinsight-302249815.html
SOURCE DelveInsight Business Research, LLP